by Janneke de Haan | Aug 1, 2024 | News, Publications
In-depth cross-validation of human and mouse CD4-specific minibodies for noninvasive PET imaging JOURNAL ARTICLE Abstract: In-depth cross-validation of human and mouse CD4-specific minibodies for noninvasive PET imaging of CD4+ cells and response prediction to cancer...
by Janneke de Haan | Jun 25, 2024 | Interview, News
Anne van der Waaij: "The main goal of the research was to see where vedolizumab goes in the body and which cells it affects" WE INTERVIEWED ANNE ABOUT HER PUBLISHED PAPER What was the goal of your research? Choosing the right treatment like vedolizumab for patients...
by Janneke de Haan | Jun 20, 2024 | News, Publications
Navigating the landscape of PD-1/PD-L1 imaging tracers: from challenges to opportunities PAPER Introduction Immunotherapy targeted to immune checkpoint inhibitors, such as the program cell death receptor (PD-1) and its ligand (PD-L1), has revolutionized cancer...
by Anne-Fleur | Jun 14, 2024 | News, Publications
Fluorescently labelled vedolizumab to visualise drug distribution and mucosal target cells in inflammatory bowel disease ABSTRACT Objective Improving patient selection and development of biological therapies such as vedolizumab in IBD requires a thorough understanding...
by Daisy van Schaijik | May 8, 2024 | News, Publications
Non-specific irreversible 89Zr-mAb uptake in tumours: evidence from biopsy-proven target-negative tumours using 89Zr-immuno-PET Abstract Background Distribution of mAbs into tumour tissue may occur via different processes contributing differently to the 89Zr-mAb...
by Daisy van Schaijik | May 8, 2024 | News, Publications
89Zr-Immuno-PET with Immune Checkpoint Inhibitors: Measuring Target Engagement in Healthy Organs Introduction 89Zr-immuno-PET (positron emission tomography with zirconium-89-labeled monoclonal antibodies ([89Zr]Zr-mAbs)) can be used to study the biodistribution of...
Recent Comments